TET2 and congestive heart failure: Thus, LOY ≥17%, which co‐occurs with DNMT3A/TET2 CHIP‐driver mutations in more than 20% of all cases studied and occurs in 27.1% of all patients at the age above 70 years, appears to be an independent predictor of mortality in patients with HFrEF and is a major determinant of increased mortality in DNMT3A/TET2 CHIP‐driver mutation carriers with chronic heart failure.